Beta
ManageChatDiscover
201649

Micronucleus Assay in Patients with Lung Cancer, Chronic Obstructive Pulmonary Disease and Non-Smoker Control

Article

Last updated: 03 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

During the last decades, cytogenetic markers in peripheral blood lymphocytes have been used to assess exposure to carcinogenic or mutagenic agents. This study was conducted with the aim of assessing the use of micronucleus [MN] assay as a marker in lung cancer and whether this method could predict cancer risk in patients with chronic obstructive pulmonary disease [COPD] as it is known that lung cancer is far more common in patients with COPD than in those with normal airflow. The study included 96 male subjects; 40 patients with lung cancer, 36 patients with COPD and 20 control subjects. Twenty five percent of cases with lung cancer and 86.1% of cases with COPD had MN frequency ranging from < 5-<15 MN/500 cytokinesis blocked [CB] binucleated cells compared to 100% in the control group. Forty percent of cases with lung cancer and 13.9% of cases with COPD had 15-20 MN/500 CB binucleated cells. Thirty five percent of cases with lung cancer had 20-25 MN/500 CB binucleated cells. These differences are statistically significant [X2= 75.2, p < 0.000]. In the lung cancer group, the mean MN/500 CB binucleated cells was 18.4±4.2 [range:12-27 MN/500 CB binucleated cells], in the group with COPD, the mean MN/500 CB binucleated cells was 8.3+4.1 [range:1-17 MN/500 CB binucleated cells] with 8 patients [22.2%] having MN in the cancer range, i.e. 12-17. The mean MN/500 CB binucleated cells of the control group was 5.4±2.5 [range:2-12 MN/500 CB binucleated cells]. These differences are statistically significant [least significant difference test]. All cases with lung cancer/and 63.9% of cases with COPD had mean MN frequency greater than the upper 95% CI of the mean MN frequency for the control group. Applying logistic regression analysis for the effect of risk factors revealed that lung cancer patients who were current or ex smokers had significantly higher MN frequencies than patients with COPD. The elevated levels of micronuclei in patients with lung cancer implies that micronucleus assay could be used as a method to detect cancer. Patients suffering from COPD who have elevated levels of micronuclei need to be followed up closely.

DOI

10.21608/jhiph.2002.201649

Keywords

micronucleus assay, Lung Cancer, Chronic Obstructive, pulmonary disease, Non-Smoker Control

Authors

First Name

Soha

Last Name

Kholeif

MiddleName

F.

Affiliation

Human Genetics Department, Medical Research Institute, Alexandria University, Egypt

Email

-

City

-

Orcid

-

First Name

Mohamed

Last Name

Mokhtar

MiddleName

M.

Affiliation

Human Genetics Department, Medical Research Institute, Alexandria University, Egypt

Email

-

City

-

Orcid

-

First Name

Mahmoud

Last Name

Ibrahim

MiddleName

M.

Affiliation

Chest Department, Faculty of Medicine, University of Alexandria, Egypt

Email

-

City

-

Orcid

-

First Name

Nadia

Last Name

Abd El Monem

MiddleName

A.

Affiliation

Department of Radiation Sciences [Clinical Oncology Unit], Medical Research Institute, University of Alexandria, Egypt

Email

-

City

-

Orcid

-

Volume

32

Article Issue

4

Related Issue

27972

Issue Date

2002-10-01

Receive Date

2021-10-27

Publish Date

2002-10-01

Page Start

665

Page End

676

Print ISSN

2357-0601

Online ISSN

2357-061X

Link

https://jhiphalexu.journals.ekb.eg/article_201649.html

Detail API

https://jhiphalexu.journals.ekb.eg/service?article_code=201649

Order

1

Type

Original Article

Type Code

511

Publication Type

Journal

Publication Title

Journal of High Institute of Public Health

Publication Link

https://jhiphalexu.journals.ekb.eg/

MainTitle

Micronucleus Assay in Patients with Lung Cancer, Chronic Obstructive Pulmonary Disease and Non-Smoker Control

Details

Type

Article

Created At

22 Jan 2023